Lipid-lowering drugs

Y. Hirakawa, H. Shimokawa

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Accumulating evidences in recent major clinical studies have shown the importance of anti-hyperlipidemic treatment in preventing atherosclerotic cardiovascular diseases. Lipid-lowering drugs can be divided into HMG-CoA reductase inhibitors (statins), bile-acid sequestrants (resins), nicotinic acid, fibrates and probucol. Among them, statins had revolutionary impact on the treatment of hyperlipidemia since pravastatin, which was developed in Japan, was launched in 1989. Several lipid-lowering drugs are now under development in Japan, including pitavastatin, rosuvastatin, F-1394 (ACAT inhibitor), CS-505 (ACAT inhibitor) and NO-1886 (LPL activator). In this review, characteristics of these new lipid-lowering drugs will be discussed.

Original languageEnglish
Pages (from-to)389-395
Number of pages7
JournalFolia Pharmacologica Japonica
Issue number6
Publication statusPublished - 2001


  • F-1394
  • Gemfibrozil
  • NO-1886
  • Pitavastatin
  • Rosuvastatin

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Lipid-lowering drugs'. Together they form a unique fingerprint.

Cite this